rsPSMA + Alhydrogel

The drug "rsPSMA + Alhydrogel" appears to be a vaccine formulation consisting of purified recombinant PSMA (rsPSMA) protein adsorbed to Alhydrogel adjuvant[1]. Alhydrogel is an aluminum hydroxide wet gel suspension that serves as an adjuvant to enhance immune responses[3]. ## Composition and Mechanism Alhydrogel (aluminum hydroxide) is a widely used vaccine adjuvant that works through several mechanisms: - It forms a depot at the injection site, enabling enhanced antigen availability - It activates antigen presenting cells (APCs) and improves uptake by immune cells - It can activate innate immunity pathways triggered by pattern recognition receptors (PRRs) - It has been shown to activate the NLRP3 inflammasome, though its role in antibody response is debated[3] Alhydrogel particles have a net positive electrical charge at pH 5-7, making them well-suited for adsorption of negatively charged antigens[3]. The rsPSMA protein component likely targets prostate-specific membrane antigen (PSMA), which is a protein expressed in prostate cancer cells. ## Formulation Properties The binding of antigens to Alhydrogel can be affected by various factors: - Phosphate concentration can diminish the extent and strength of antigen-adjuvant binding - The pH of the formulation affects binding properties - Preservatives like thimerosal can potentially impact the stability of Alhydrogel-adsorbed antigens[2] Based on the available information, this appears to be an investigational vaccine formulation, though specific clinical trial information for this exact combination is not provided in the search results.

Other names

recombinant soluble prostate-specific membrane antigenrsPSMA protein plus Alhydrogel vaccine